➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Colorcon

Last Updated: July 30, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ladarixin


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Ladarixin?

Ladarixin is an investigational drug.

There have been 4 clinical trials for Ladarixin. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2020.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 1, Diabetes Mellitus, and [disabled in preview]. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A and [disabled in preview].

There are nine US patents protecting this investigational drug and sixty-five international patents.

Recent Clinical Trials for Ladarixin
TitleSponsorPhase
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.Dompé Farmaceutici S.p.APhase 2
A Phase 3 Randomized, Controlled Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell FunctionDompé Farmaceutici S.p.APhase 3
A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy VolunteersDompé Farmaceutici S.p.APhase 1

See all Ladarixin clinical trials

Clinical Trial Summary for Ladarixin

Top disease conditions for Ladarixin
Top clinical trial sponsors for Ladarixin

See all Ladarixin clinical trials

US Patents for Ladarixin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ladarixin ⤷  Free Forever Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Free Forever Trial
Ladarixin ⤷  Free Forever Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Free Forever Trial
Ladarixin ⤷  Free Forever Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) ⤷  Free Forever Trial
Ladarixin ⤷  Free Forever Trial Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) ⤷  Free Forever Trial
Ladarixin ⤷  Free Forever Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) ⤷  Free Forever Trial
Ladarixin ⤷  Free Forever Trial Method for treating cancer using dual antagonists of CXCR1 and CXCR2 Syntrix Biosystems Inc. (Auburn, WA) ⤷  Free Forever Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ladarixin

Drugname Country Document Number Estimated Expiration Related US Patent
Ladarixin Australia AU2017261372 2036-05-05 ⤷  Free Forever Trial
Ladarixin Canada CA3023278 2036-05-05 ⤷  Free Forever Trial
Ladarixin China CN107847398 2036-05-05 ⤷  Free Forever Trial
Ladarixin European Patent Office EP3452003 2036-05-05 ⤷  Free Forever Trial
Ladarixin Hong Kong HK1249728 2036-05-05 ⤷  Free Forever Trial
Ladarixin Japan JP2019520866 2036-05-05 ⤷  Free Forever Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Medtronic
Express Scripts
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.